A NEW APPROACH TO CHEMOEMBOLIZATION FOR UNRESECTABLE HEPATOCELLULAR-CARCINOMA USING ACLARUBICIN MICROSPHERES IN COMBINATION WITH CISPLATIN SUSPENDED IN IODIZED OIL
A NEW APPROACH TO CHEMOEMBOLIZATION FOR UNRESECTABLE HEPATOCELLULAR-CARCINOMA USING ACLARUBICIN MICROSPHERES IN COMBINATION WITH CISPLATIN SUSPENDED IN IODIZED OIL
复制标题
DOI：
10.1002/1097-0142(19911215)68:12
复制
发表时间：
1991-12-15
期刊：
影响因子：
6.2
通讯作者：
OGAWA, M
中科院分区：
文献类型：
--
作者：
BEPPU, T;OHARA, C;OGAWA, M
连续66例不可切除的肝细胞癌（HCC）患者接受阿克拉比星微球（ACRms）联合碘化油悬浮顺铂（Lipiodol, Laboratoire Guerbert, Paris, France） （CSL）经导管动脉化疗栓塞（TACE）治疗。疾病分期如下：I期（n = 1）， II期（n = 10）， III期（n = 26）和IV期（n = 29）。通过比较ACRms加CSL和ACRms不加CSL来评估TACE的有效性。在66例ACRms和CSL治疗的患者中，62例（93.9%）可以检查反应。根据反应标准，部分反应31例（50.0%），轻微反应17例（27.4%）。13例（21.0%）无变化，1例（1.6%）有进展性疾病。1年累积生存率为80.7%，2年为64.2%，3年为50.6%。这些比率明显高于ACRms治疗组。ACRms和CSL组11例患者出现临床并发症：胆囊炎（4.5%）、胰腺炎（3.0%）、肝脓肿（3.0%）、肝功能衰竭（3.0%）、胃肠道出血（1.5%）、肾功能衰竭（1.5%）。未观察到与治疗相关的致命副作用。使用ACRms联合CSL的TACE延长了不可切除的HCC患者的生存期。
Sixty-six consecutive patients with unresectable hepatocellular carcinoma (HCC) were treated with transcatheter arterial chemoembolization (TACE) using aclarubicin microspheres (ACRms) in combination with cisplatin suspended in iodized oil (Lipiodol, Laboratoire Guerbert, Paris, France) (CSL). The stages of the disease were as follows: Stage I (n = 1), Stage II (n = 10), Stage III (n = 26), and Stage IV (n = 29). The effectiveness of TACE was assessed by comparing ACRms with CSL with ACRms without CSL. Of 66 patients treated with ACRms and CSL, 62 (93.9%) could be examined for response. According to response criteria, there were 31 (50.0%) partial responses and 17 (27.4%) minor responses. In 13 cases (21.0%) there was no change and in 1 case (1.6%) there was progressive disease. The cumulative survival rate was 80.7% at 1 year, 64.2% at 2 years, and 50.6% at 3 years. The rates were significantly higher than those of the group treated with ACRms. Eleven patients in the ACRms and CSL group experienced clinical complications: cholecystitis (4.5%), pancreatitis (3.0%), liver abscess (3.0%), hepatic failure (3.0%), gastrointestinal bleeding (1.5%), and renal failure (1.5%). No lethal side effects related to the therapy were observed. TACE using ACRms in combination with CSL prolongs the survival of patients with unresectable HCC.